{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:20:39Z","timestamp":1790565639248,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Lichen planus (LP) is a chronic inflammatory T-cell mediated disease affecting the skin, mucous membranes and skin appendages. Data on clinical phenotypes and systemic treatment of LP are limited. We analyzed a cohort of LP patients (equal or older than 18\u00a0years) regarding their clinical phenotypes (subtype, demographics, comorbidities) and treatment. Patients were selected from 2017 to 2023 who were seen in our outpatient clinic during a treatment period of at least 2\u00a0years. We identified 85 patients (62 females, 73% and 76 above 50\u00a0years; 89%) who met selection criteria. 33 had oral LP (39%), 23 had cutaneous LP (27%) and 2% had both or other manifestations (32%). Frequent comorbidities were hypertension (n\u2009=\u200940), hypothyroidism (n\u2009=\u200917), asthma (n\u2009=\u200911), diabetes (n\u2009=\u200910) and dyslipidemia (n\u2009=\u20098). 44% were taking a medication known to favor LP onset. 2\/85 patients had a malignant transformation. 33 patients were treated topically and 50 required systemic therapy. Hydroxychloroquine (HCQ) (n\u2009=\u200918; 36%) and retinoids (n\u2009=\u200917; 34%) were the most commonly used systemic medications. Both were efficacious as determined by the investigator global response reaching rates 78% and 71%, respectively. The tolerability of retinoids was lower than HCQ (adverse event rate 29% versus 6%). Our results confirm previous data on clinical phenotypes and comorbidity patterns in LP patients. The treatment assessment suggests that HCQ may be an efficacious and safe first-line treatment for mucosal lichen planus. Further data from prospective controlled clinical trials are needed to prove the optimal treatment approach for different clinical phenotypes of LP.<\/jats:p>","DOI":"10.1007\/s00403-025-04226-7","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:44:54Z","timestamp":1744717494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hydroxychloroquine is safe and efficacious in oral lichen planus: data from a large outpatient cohort"],"prefix":"10.1007","volume":"317","author":[{"given":"Khava","family":"Abdusalamova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta","family":"Worm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzan","family":"Solimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"issue":"6","key":"4226_CR1","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/ddg.14565","volume":"19","author":"F Solimani","year":"2021","unstructured":"Solimani F, Forchhammer S, Schloegl A, Ghoreschi K, Meier K (2021) Lichen planus\u2014a clinical guide. J Dtsch Dermatol Ges 19(6):864\u2013882. https:\/\/doi.org\/10.1111\/ddg.14565","journal-title":"J Dtsch Dermatol Ges"},{"issue":"8","key":"4226_CR2","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/ddg","volume":"20","author":"E Schruf","year":"2022","unstructured":"Schruf E, Biermann MH, Jacob J, H\u00e4ckl D, Reinhardt M, Hertl M, Wohlrab J (2022) Lichen planus in Germany\u2014epidemiology, treatment, and comorbidity. A retrospective claims data analysis. J Dtsch Dermatol Ges 20(8):1101\u20131110. https:\/\/doi.org\/10.1111\/ddg","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"4226_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/ddg.12031","volume":"11","author":"G Wagner","year":"2013","unstructured":"Wagner G, Rose C, Sachse MM (2013) Clinical variants of lichen planus. J Dtsch Dermatol Ges 11(4):309\u2013319. https:\/\/doi.org\/10.1111\/ddg.12031","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"4226_CR4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamadermatol.2019.3797","volume":"156","author":"C Li","year":"2020","unstructured":"Li C, Tang X, Zheng X, Ge S, Wen H, Lin X, Chen Z, Lu L (2020) Global prevalence and incidence estimates of oral lichen planus: a systematic review and meta-analysis. JAMA Dermatol 156(2):172\u2013181. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3797","journal-title":"JAMA Dermatol"},{"issue":"2","key":"4226_CR5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/exd.14226","volume":"30","author":"K Pietschke","year":"2021","unstructured":"Pietschke K, Holstein J, Meier K, Sch\u00e4fer I, M\u00fcller-Hermelink E, Gonzalez-Menendez I, Quintanilla-Martinez L, Ghoreschi FC, Solimani F, Ghoreschi K (2021) The inflammation in cutaneous lichen planus is dominated by IFN-\u03d2 and IL-21-A basis for therapeutic JAK1 inhibition. Exp Dermatol 30(2):262\u2013270. https:\/\/doi.org\/10.1111\/exd.14226","journal-title":"Exp Dermatol"},{"issue":"4","key":"4226_CR6","doi-asserted-by":"publisher","first-page":"e15080","DOI":"10.1111\/exd.15080","volume":"33","author":"KN Stolte","year":"2024","unstructured":"Stolte KN, Mesas-Fern\u00e1ndez A, Meier K, Klein EK, Dommisch H, Ghoreschi K, Solimani F (2024) TYK2 inhibition with deucravacitinib ameliorates erosive oral lichen planus. Exp Dermatol 33(4):e15080. https:\/\/doi.org\/10.1111\/exd.15080","journal-title":"Exp Dermatol"},{"key":"4226_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19069","author":"F Solimani","year":"2023","unstructured":"Solimani F, Mesas-Fern\u00e1ndez A, Dilling A, Nast A, Hilke FJ, Ghoreschi FC, Worm M, Ghoreschi K, Meier K (2023) The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus. J Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.19069","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"4226_CR8","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.jaci.2020.01.031","volume":"145","author":"W Damsky","year":"2020","unstructured":"Damsky W, Wang A, Olamiju B, Peterson D, Galan A, King B (2020) Treatment of severe lichen planus with the JAK inhibitor tofacitinib. J Allergy Clin Immunol 145(6):1708-1710.e2. https:\/\/doi.org\/10.1016\/j.jaci.2020.01.031","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"4226_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jaci.2018.02.044","volume":"142","author":"T Schmidt","year":"2018","unstructured":"Schmidt T, Solimani F, Pollmann R, Stein R, Schmidt A, Stulberg I, K\u00fchn K, Eming R, Eubel V, Kind P, Arweiler N, Sitaru C, Hertl M (2018) TH1\/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus. J Allergy Clin Immunol 142(2):669-672.e7. https:\/\/doi.org\/10.1016\/j.jaci.2018.02.044","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"4226_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/ddg.15270","volume":"22","author":"DD Kanatoula","year":"2024","unstructured":"Kanatoula DD, Bodner E, Ghoreschi K, Meier K, Solimani F (2024) Non-biologic immunosuppressive drugs for inflammatory and autoimmune skin diseases. J Dtsch Dermatol Ges 22(3):400\u2013421. https:\/\/doi.org\/10.1111\/ddg.15270","journal-title":"J Dtsch Dermatol Ges"},{"key":"4226_CR11","doi-asserted-by":"publisher","first-page":"997190","DOI":"10.3389\/fmed.2022.997190","volume":"9","author":"D Didona","year":"2022","unstructured":"Didona D, Caposiena Caro RD, Sequeira Santos AM, Solimani F, Hertl M (2022) Therapeutic strategies for oral lichen planus: state of the art and new insights. Front Med (Lausanne) 9:997190. https:\/\/doi.org\/10.3389\/fmed.2022.997190","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"4226_CR12","doi-asserted-by":"publisher","first-page":"R155","DOI":"10.1186\/ar3895","volume":"14","author":"K Sacre","year":"2012","unstructured":"Sacre K, Criswell LA, McCune JM (2012) Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 14(3):R155. https:\/\/doi.org\/10.1186\/ar3895","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"4226_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3899\/jrheum.200726","volume":"48","author":"WM Lambers","year":"2021","unstructured":"Lambers WM, Westra J, Bootsma H, de Leeuw K (2021) Hydroxychloroquine suppresses interferon-inducible genes and B cell activating factor in patients with incomplete and new-onset systemic lupus erythematosus. J Rheumatol 48(6):847\u2013851. https:\/\/doi.org\/10.3899\/jrheum.200726","journal-title":"J Rheumatol"},{"issue":"3","key":"4226_CR14","doi-asserted-by":"publisher","first-page":"e14903","DOI":"10.1111\/dth.14903","volume":"34","author":"KM Hunt","year":"2021","unstructured":"Hunt KM, Klager S, Kwak YJ, Sami N (2021) Successful systemic treatment outcomes of lichen planus: a single-center retrospective review. Dermatol Ther 34(3):e14903. https:\/\/doi.org\/10.1111\/dth.14903","journal-title":"Dermatol Ther"},{"issue":"11","key":"4226_CR15","doi-asserted-by":"publisher","first-page":"516","DOI":"10.47102\/annals-acadmedsg.V45N11p516","volume":"45","author":"YW Yew","year":"2016","unstructured":"Yew YW, Lai YC, Chan R (2016) A retrospective cohort study of epidemiology and clinical outcome in lichen planus. Ann Acad Med Singap 45(11):516\u2013519","journal-title":"Ann Acad Med Singap"},{"issue":"1","key":"4226_CR16","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.4317\/medoral.22656","volume":"24","author":"J Cassol-Spanemberg","year":"2019","unstructured":"Cassol-Spanemberg J, Blanco-Carri\u00f3n A, Rodr\u00edguez-de Rivera-Campillo ME, Estrugo-Devesa A, Jan\u00e9-Salas E, L\u00f3pez-L\u00f3pez J (2019) Cutaneous, genital and oral lichen planus: a descriptive study of 274 patients. Med Oral Patol Oral Cir Bucal 24(1):e1\u2013e7. https:\/\/doi.org\/10.4317\/medoral.22656","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"5","key":"4226_CR17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/j.1365-2133.2006.07480.x","volume":"155","author":"P Belfiore","year":"2006","unstructured":"Belfiore P, Di Fede O, Cabibi D, Campisi G, Amar\u00f9 GS, De Cantis S, Maresi E (2006) Prevalence of vulval lichen planus in a cohort of women with oral lichen planus: an interdisciplinary study. Br J Dermatol 155(5):994\u2013998. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07480.x","journal-title":"Br J Dermatol"},{"issue":"4","key":"4226_CR18","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1111\/odi.14727","volume":"30","author":"T De Porras-Carrique","year":"2024","unstructured":"De Porras-Carrique T, Ramos-Garc\u00eda P, Gonz\u00e1lez-Moles M\u00c1 (2024) Hypertension in oral lichen planus: a systematic review and meta-analysis. Oral Dis 30(4):1793\u20131805. https:\/\/doi.org\/10.1111\/odi.14727","journal-title":"Oral Dis"},{"issue":"5","key":"4226_CR19","doi-asserted-by":"publisher","first-page":"555","DOI":"10.4103\/idoj.IDOJ_499_18","volume":"10","author":"R Singla","year":"2019","unstructured":"Singla R, Ashwini PK, Jayadev B (2019) Lichen planus and metabolic syndrome: is there a relation? Indian Dermatol Online J 10(5):555\u2013559. https:\/\/doi.org\/10.4103\/idoj.IDOJ_499_18","journal-title":"Indian Dermatol Online J"},{"issue":"8","key":"4226_CR20","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1111\/odi.13927","volume":"28","author":"N Mallah","year":"2022","unstructured":"Mallah N, Ignacio Varela-Centelles P, Seoane-Romero J, Takkouche B (2022) Diabetes mellitus and oral lichen planus: a systematic review and meta-analysis. Oral Dis 28(8):2100\u20132109. https:\/\/doi.org\/10.1111\/odi.13927","journal-title":"Oral Dis"},{"issue":"5","key":"4226_CR21","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1111\/ijd.13234","volume":"55","author":"YC Lai","year":"2016","unstructured":"Lai YC, Yew YW, Schwartz RA (2016) Lichen planus and dyslipidemia: a systematic review and meta-analysis of observational studies. Int J Dermatol 55(5):e295-304. https:\/\/doi.org\/10.1111\/ijd.13234","journal-title":"Int J Dermatol"},{"issue":"18","key":"4226_CR22","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.3390\/jcm12185777","volume":"12","author":"M Garc\u00eda-Pola","year":"2023","unstructured":"Garc\u00eda-Pola M, Rodr\u00edguez-Fonseca L, Su\u00e1rez-Fern\u00e1ndez C, Sanju\u00e1n-Pardavila R, Seoane-Romero J, Rodr\u00edguez-L\u00f3pez S (2023) Bidirectional association between lichen planus and hepatitis C\u2014an update systematic review and meta-analysis. J Clin Med 12(18):5777. https:\/\/doi.org\/10.3390\/jcm12185777","journal-title":"J Clin Med"},{"issue":"3","key":"4226_CR23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3390\/cancers16030608","volume":"16","author":"M\u00c1 Gonz\u00e1lez-Moles","year":"2024","unstructured":"Gonz\u00e1lez-Moles M\u00c1, Ramos-Garc\u00eda P (2024) An evidence-based update on the potential for malignancy of oral lichen planus and related conditions: a systematic review and meta-analysis. Cancers (Basel) 16(3):608. https:\/\/doi.org\/10.3390\/cancers16030608","journal-title":"Cancers (Basel)"},{"issue":"7","key":"4226_CR24","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/jdv.16464","volume":"34","author":"D Ioannides","year":"2020","unstructured":"Ioannides D, Vakirlis E, Kemeny L, Marinovic B, Massone C, Murphy R, Nast A, Ronnevig J, Ruzicka T, Cooper SM, Tr\u00fceb RM, Pujol Vallverd\u00fa RM, Wolf R, Neumann M (2020) European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol 34(7):1403\u20131414. https:\/\/doi.org\/10.1111\/jdv.16464","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"4226_CR25","doi-asserted-by":"publisher","first-page":"CD008092","DOI":"10.1002\/14651858.CD008092.pub2","volume":"2012","author":"S Cheng","year":"2012","unstructured":"Cheng S, Kirtschig G, Cooper S, Thornhill M, Leonardi-Bee J, Murphy R (2012) Interventions for erosive lichen planus affecting mucosal sites. Cochrane Database Syst Rev 2012(2):CD008092. https:\/\/doi.org\/10.1002\/14651858.CD008092.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"4226_CR26","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jaad.2019.04.027","volume":"81","author":"Z Schwager","year":"2019","unstructured":"Schwager Z, Stern M, Cohen J, Femia A (2019) Clinical epidemiology and treatment of lichen planus: a retrospective review of 2 tertiary care centers. J Am Acad Dermatol 81(6):1397\u20131399. https:\/\/doi.org\/10.1016\/j.jaad.2019.04.027","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"4226_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/bjd\/ljac113","volume":"188","author":"C Platais","year":"2023","unstructured":"Platais C, Lalagianni N, Momen S, Ormond M, McParland H, Setterfield J (2023) Efficacy of hydroxychloroquine in oral lichen planus: a retrospective review. Br J Dermatol 188(4):557\u2013558. https:\/\/doi.org\/10.1093\/bjd\/ljac113","journal-title":"Br J Dermatol"},{"issue":"5","key":"4226_CR28","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1111\/odi.14746","volume":"30","author":"Y Xie","year":"2024","unstructured":"Xie Y, Xu H, Li C, Wang Y, Lu R, Hua H, Tang G, Zhou G, Jin X, Shang Q, Dan P, Zhang C, Luo X, Dan H, Zeng X, Zhou Y, Chen Q (2024) Hydroxychloroquine is effective in oral lichen planus: a multicenter, randomized, controlled trial. Oral Dis 30(5):3126\u20133135. https:\/\/doi.org\/10.1111\/odi.14746","journal-title":"Oral Dis"},{"issue":"3","key":"4226_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jaad.2009.08.054","volume":"62","author":"C Chiang","year":"2010","unstructured":"Chiang C, Sah D, Cho BK, Ochoa BE, Price VH (2010) Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. J Am Acad Dermatol 62(3):387\u2013392. https:\/\/doi.org\/10.1016\/j.jaad.2009.08.054","journal-title":"J Am Acad Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04226-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04226-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04226-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:44:55Z","timestamp":1744717495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04226-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4226"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04226-7","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MW received fees for clinical studies and\/or speaker activities from Abbvie, Eli Lilly and Pfizer. The other co\u2010authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"711"}}